Select area to zoom
Created with Highcharts 11.1.0Jul '24Oct '24Jan '25Apr '2520.004.39

Profile

Edit
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
URL https://www.karyopharm.com
Investor Relations URL https://investors.karyopharm.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 06, 2025 (est.)
Last Earnings Release May. 12, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
URL https://www.karyopharm.com
Investor Relations URL https://investors.karyopharm.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 06, 2025 (est.)
Last Earnings Release May. 12, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows